Inovio Pharmaceuticals Archives - Medical Design Sourcing

Inovio names new chief medical officer

Inovio (Nasdaq:INO) announced today that it appointed Dr. Michael Sumner as its new chief medical officer (CMO).

Sumner will oversee Inovio’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, along with regulatory affairs, pharmacovigilance and medical affairs.

He will also serve on the company’s executive leadership team and report to President and CEO Dr. Jacqueline Shea in his role at the Plymouth Meeting, Pennsylvania-based developer of vaccines and vaccine delivery technology.

Get the full story at our sister site, Drug Delivery Business News.

Inovio shares down on missed Q2 projections as it moves forward with COVID-19 vaccine

Inovio Pharmaceuticals (NSDQ:INO) shares took a hit this morning on second-quarter results that missed the consensus forecast.

INO shares were down more than –11% at $8.53 per share in morning trading today.

Get the full story at our sister site, Drug Delivery Business News.

Inovio slides before hours on missed Q2 projections

Inovio Pharmaceuticals (NSDQ:INO) shares took a hit this morning on second-quarter results that missed the consensus forecast.

INO shares were down -4.7% at $9.15 per share before the market opened today.

Get the full story at our sister site, Drug Delivery Business News.

Inovio Pharmaceuticals posts Street-beating Q4, touts HPV trial results

Inovio Pharmaceuticals (NSDQ:INO) shares dipped after hours today after the company presented its fourth-quarter earnings and touted clinical trial results.

INO shares finished the day up 4.5% at $11.60 per share but have since dropped -2.2% after hours to $11.35 per share.

The Plymouth Meeting, Pa.-based company posted losses of -$24.3 million, or -14¢ per share, on sales of $5.6 million for the three months ended Dec. 31, 2020, for a 35.5% bottom-line gain on massive sales growth from revenues of just $279,000 in the fourth quarter of 2019.

Get the full story at our sister site, Drug Delivery Business News.

8 drug delivery innovations you need to know

The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon.

Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means.

Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.

Here are eight types of drug delivery innovations you should know:

Next>>

8 drug delivery innovations you need to know

The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon.

Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means.

Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.

Here are eight types of drug delivery innovations you should know:

Next>>

MedTech 100 roundup: Stocks brought back down again

A week after topping pre-pandemic highs, the medtech industry’s stocks were brought back down to earth in quick fashion.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 89.03 (Sep. 11), marking a -0.3% dip from the 89.29 points registered at the end of the week prior (Sep. 4).

However, the slight dip from week-to-week doesn’t show that, just before the Sep. 4 mark, medtech stocks had reached 93.11 points on Sep. 2, coming in nearly a full point ahead of the pre-pandemic high of 92.32, which the market reached on Feb. 19.

During the week, the index dipped down to 88.22 points, which is the lowest total it has reached since it sat at 87.06 on July 16. By climbing back up to 89.03, the index now represents a -4.4% drop from the Sep. 2 high point and a -3.6% drop from the pre-pandemic high set on Feb. 19.

Meanwhile, the S&P 500 Index saw a -2.5% dip from Sep…

Thermo Fisher to manufacture Inovio COVID-19 vaccine candidate

Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate.

Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by 2021, subject to FDA approval.

Get the full story at our sister site, Drug Delivery Business News.

Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device.

Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver INO-4800 directly into the skin. It may also be used to deliver a potential COVID-19 vaccine.

Get the full story at our sister site, Drug Delivery Business News.

Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device.

Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver INO-4800 directly into the skin. It may also be used to deliver a potential COVID-19 vaccine.

Get the full story at our sister site, Drug Delivery Business News.

Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device.

Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver INO-4800 directly into the skin. It may also be used to deliver a potential COVID-19 vaccine.

The small, portable, hand-held device that runs in “AA” batteries is designed to deliver the INO-4800 vaccine where it prompts the body’s immune system to drive an immune response. It is currently in the midst of a U.S. Phase I clinical trial, for which results will be available later this month. A Phase II/III efficacy trial is slated to begin this month or next.

Plymouth Meeting, Pa.-based Inovio said in a news release that its San Diego manufacturing facility has produced initial quantities of the device and displayed capabilities for scale-…